Literature DB >> 9603214

In vitro studies of ferritin iron release and neurotoxicity.

K L Double1, M Maywald, M Schmittel, P Riederer, M Gerlach.   

Abstract

The increase in brain iron associated with several neurodegenerative diseases may lead to an increased production of free radicals via the Fenton reaction. Intracellular iron is usually tightly regulated, being bound by ferritin in an insoluble ferrihydrite core. The neurotoxin 6-hydroxydopamine (6-OHDA) releases iron from the ferritin core by reducing it to the ferrous form. Iron release induced by 6-OHDA and structurally related compounds and two other dopaminergic neurotoxins, 1-methyl-4-phenylpyridinium iodide (MPP+) and 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), were compared, to identify the structural characteristics important for such release. 1,2,4-Trihydroxybenzene (THB) was most effective in releasing ferritin-bound iron, followed by 6-OHDA, dopamine, catechol, and hydroquinone. Resorcinol, MPP , and TaClo were ineffective. The ability to release iron was associated with a low oxidation potential. It is proposed that a low oxidation potential and an ortho-dihydroxyphenyl structure are important in the mechanism by which ferritin iron is mobilized. In the presence of ferritin, both 6-OHDA and THB strongly stimulated lipid peroxidation, an effect abolished by the addition of the iron chelator deferoxamine. These results suggest that ferritin iron release contributes to free radical-induced cell damage in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603214     DOI: 10.1046/j.1471-4159.1998.70062492.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  34 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  EPC-K1, a hydroxyl radical scavenger, prevents 6-hydroxydopamine-induced dopamine depletion in the mouse striatum by up-regulation of catalase activity.

Authors:  H Kabuto; I Yokoi; E Iwata-Ichikawa; N Ogawa
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

3.  Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity.

Authors:  Robert A Bermel; Srinivas R Puli; Richard A Rudick; Bianca Weinstock-Guttman; Elizabeth Fisher; Frederick E Munschauer; Rohit Bakshi
Journal:  Arch Neurol       Date:  2005-09

4.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

6.  Iron in neurodegenerative disorders.

Authors:  D. Berg; G. Becker; P. Riederer; O. Riess
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 7.  Mitochondrial iron metabolism and its role in neurodegeneration.

Authors:  Maxx P Horowitz; J Timothy Greenamyre
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  Chronic expression of H-ferritin in dopaminergic midbrain neurons results in an age-related expansion of the labile iron pool and subsequent neurodegeneration: implications for Parkinson's disease.

Authors:  Deepinder Kaur; Subramanian Rajagopalan; Julie K Andersen
Journal:  Brain Res       Date:  2009-08-21       Impact factor: 3.252

9.  Docosahexaenoic acid enhances iron uptake by modulating iron transporters and accelerates apoptotic death in PC12 cells.

Authors:  Eldi Schonfeld; Ilanit Yasharel; Ephraim Yavin; Annette Brand
Journal:  Neurochem Res       Date:  2007-06-06       Impact factor: 3.996

10.  Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders.

Authors:  Genaro G Ortiz; Gloria A Benítez-King; Sergio A Rosales-Corral; Fermín P Pacheco-Moisés; Irma E Velázquez-Brizuela
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.